Patents by Inventor Heather Hobbs

Heather Hobbs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS
    Publication number: 20220306623
    Abstract: The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): wherein R1, R2, R3, R4, R4? and R5 are as defined in the description and claims; and compounds or pharmaceutically acceptable salts thereof of formulas (II), (IIa), (IIb), (IIc), and (III) having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions which include a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 29, 2022
    Inventors: Sophie Marie BERTRAND, Heather HOBBS, Simon Marc NICOLLE, Sandeep PAL, Simon PEACE, Margarita PUENTE-FELIPE
  • Chemical compounds
    Patent number: 11254671
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Gianpaolo Bravi, Heather Hobbs, Graham George Adam Inglis, Simon Nicolle, Simon Peace
  • CHEMICAL COMPOUNDS
    Publication number: 20210238162
    Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 5, 2021
    Inventors: Rodolfo CADILLA, David Norman DEATON, Ashley Paul HANCOCK, Heather HOBBS, Simon Teanby HODGSON, Andrew L. LARKIN, Joelle LE, Paul N. MORTENSON, Daniel J. PRICE, Gordon SAXTY, Lee T. SCHALLER, Christie SCHULTE, Ian Edward David SMITH, Stephen Andrew THOMSON, Joseph Wendell WILSON
  • CHEMICAL COMPOUNDS
    Publication number: 20210163472
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 3, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Gianpaolo BRAVI, Heather HOBBS, Graham George Adam INGLIS, Simon NICOLLE, Simon PEACE
  • Pyrazole derivatives used as CCR4 receptor antagonists
    Patent number: 8357716
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: January 22, 2013
    Assignee: Glaxo Group Limited
    Inventors: Heather Hobbs, Simon Teanby Hodgson, Yannick Maurice LaCroix, Deborah Needham, Nigel James Parr, Panayiotis Alexandrou Procopiou, Timothy John Ritchie, Michael David Woodrow
  • Pyrazole Derivatives Used as CCR4 Receptor Antagonists
    Publication number: 20120015932
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: February 24, 2010
    Publication date: January 19, 2012
    Inventors: Heather Hobbs, Simon Teanby Hodgson, Yannick Maurice LaCroix, Deborah Needham, Nigel James Parr, Panayiotis Alexandrou Procopiou, Timothy John Ritchie, Michael David Woodrow
  • PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS
    Publication number: 20100179139
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 15, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS
    Publication number: 20100075953
    Abstract: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 25, 2010
    Applicant: Glaxo Group Limited
    Inventors: Rachael Ancliff, Colin David Eldred, Ashley Paul Hancock, Thomas Daniel Heightman, Heather Hobbs, Simon Teanby Hodgson, David Matthew Wilson
  • PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS
    Publication number: 20100035917
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: February 11, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • Medicinal Compounds
    Publication number: 20090105309
    Abstract: Compounds of formula (I): and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective ?2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: October 20, 2004
    Publication date: April 23, 2009
    Applicant: GLAXO GROUP LIMITED
    Inventors: Philip Charles Box, Diane Mary Coe, Heather Hobbs
  • NOVEL COMPOUNDS
    Publication number: 20080176891
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: July 24, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • NOVEL COMPOUNDS
    Publication number: 20080146606
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: June 19, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
    Publication number: 20060025404
    Abstract: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
    Type: Application
    Filed: October 14, 2003
    Publication date: February 2, 2006
    Inventors: Rachel Ancliff, Colin Eldred, Yvonne Fogden, Ashley Hancock, Thomas Heightman, Heather Hobbs, Simon Hodgson, Matthew Lindon, David Wilson
  • Compounds
    Publication number: 20060019964
    Abstract: 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a derivative thereof.
    Type: Application
    Filed: April 22, 2005
    Publication date: January 26, 2006
    Inventors: Ranchael Ancliff, Colin Eldred, Yvonne Fogden, Ashley Hancock, Thomas Heightman, Heather Hobbs, Simon Hodgson, Matthew Lindon, David Wilson
  • 2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives
    Patent number: 6534486
    Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: March 18, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: David George Allen, Chuen Chan, Caroline Mary Cook, Richard Peter Charles Cousins, Brian Cox, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Stephen Swanson, Caroline Whitworth, David Bays
  • 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Patent number: 6528494
    Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 4, 2003
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
  • 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
    Patent number: 6495528
    Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: December 17, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: David George Allen, Chuen Chan, Richard Peter Charles Cousins, Brian Cox, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Thomas Davis Roper, IV, Shiping Xie
  • 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Patent number: 6426337
    Abstract: There are provided according to the invention novel compounds of formula (I) wherein R1, R2, and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: July 30, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
  • 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
    Publication number: 20020086850
    Abstract: There are provided according to the invention novel compounds of formula I 1
    Type: Application
    Filed: December 19, 2001
    Publication date: July 4, 2002
    Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, Joanna Victoria Geden